Literature DB >> 27342460

Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Amelia Ruffatti1,2, Ariela Hoxha3, Maria Favaro3, Marta Tonello3, Anna Colpo4, Umberto Cucchini5, Alessandra Banzato5, Vittorio Pengo5.   

Abstract

Most investigators currently advocate prophylactic-dose heparin plus low-dose aspirin as the preferred treatment of otherwise healthy women with obstetric antiphospholipid syndrome, whilst women with a history of vascular thrombosis alone or associated with pregnancy morbidity are usually treated with therapeutic heparin doses in association with low-dose aspirin in an attempt to prevent both thrombosis and pregnancy morbidity. However, the protocols outlined above fail in about 20 % of pregnant women with antiphospholipid syndrome. Identifying risk factors associated with pregnancy failure when conventional therapies are utilized is an important step in establishing guidelines to manage these high-risk patients. Some clinical and laboratory risk factors have been found to be related to maternal-foetal complications in pregnant women on conventional therapy. However, the most efficacious treatments to administer to high-risk antiphospholipid syndrome women in addition to conventional therapy in order to avoid pregnancy complications are as yet unestablished. This is a comprehensive review on this topic and an invitation to participate in a multicentre study in order to identify the best additional treatments to be used in this subset of antiphospholipid syndrome patients.

Entities:  

Keywords:  Additional treatment; Obstetric antiphospholipid syndrome; Risk factor; Treatment

Mesh:

Substances:

Year:  2017        PMID: 27342460     DOI: 10.1007/s12016-016-8571-6

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  97 in total

Review 1.  Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.

Authors:  Patrick Cherin; Isabelle Marie; Mauricette Michallet; Eric Pelus; Jacques Dantal; Jean-Charles Crave; Jean-Christophe Delain; Jean-François Viallard
Journal:  Autoimmun Rev       Date:  2015-09-16       Impact factor: 9.754

2.  Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant.

Authors:  Thomas Sailer; Claudia Zoghlami; Christine Kurz; Helmut Rumpold; Peter Quehenberger; Simon Panzer; Ingrid Pabinger
Journal:  Thromb Haemost       Date:  2006-05       Impact factor: 5.249

3.  In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti-idiotypic mechanism.

Authors:  M Galli; S Cortelazzo; T Barbui
Journal:  Am J Hematol       Date:  1991-11       Impact factor: 10.047

Review 4.  The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.

Authors:  Arsène Mekinian; Maria Grazia Lazzaroni; Anna Kuzenko; Jaume Alijotas-Reig; Amelia Ruffatti; Pierre Levy; Valentina Canti; Katarina Bremme; Holy Bezanahary; Tiziana Bertero; Robin Dhote; Francois Maurier; Laura Andreoli; Amélie Benbara; Ahmed Tigazin; Lionel Carbillon; Pascale Nicaise-Roland; Angela Tincani; Olivier Fain
Journal:  Autoimmun Rev       Date:  2015-01-21       Impact factor: 9.754

Review 5.  Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  Laura Andreoli; Micaela Fredi; Cecilia Nalli; Rossella Reggia; Andrea Lojacono; Mario Motta; Angela Tincani
Journal:  J Autoimmun       Date:  2011-12-26       Impact factor: 7.094

6.  Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies.

Authors:  Y Nakamura; K Yoshida; S Itoh; Y Kanai; H Tsuda; H Hashimoto; N Mitsuhashi; Y Kuwabara
Journal:  Am J Reprod Immunol       Date:  1999-05       Impact factor: 3.886

7.  Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.

Authors:  Hannah L Rose; Wai Khoon Ho
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

8.  Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.

Authors:  Adriana Danowski; Mario Newton Leitão de Azevedo; Jose Angelo de Souza Papi; Michelle Petri
Journal:  J Rheumatol       Date:  2009-05-15       Impact factor: 4.666

9.  Hepatic infarctions during pregnancy are associated with the antiphospholipid syndrome and in addition with complete or incomplete HELLP syndrome.

Authors:  R Pauzner; M Dulitzky; H Carp; H Mayan; R Kenett; Z Farfel; A Many
Journal:  J Thromb Haemost       Date:  2003-08       Impact factor: 5.824

10.  High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome.

Authors:  J Arnout; B Spitz; C Wittevrongel; M Vanrusselt; A Van Assche; J Vermylen
Journal:  Thromb Haemost       Date:  1994-06       Impact factor: 5.249

View more
  6 in total

1.  Characteristics of pregnancy complications and treatment in obstetric antiphospholipid syndrome in China.

Authors:  Zhuochao Zhou; Jialin Teng; Yue Sun; Honglei Liu; Xiaobing Cheng; Yutong Su; Chengde Yang; Junna Ye
Journal:  Clin Rheumatol       Date:  2019-07-09       Impact factor: 2.980

Review 2.  Autoimmunity in 2016.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 3.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

Review 4.  Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome.

Authors:  Juan J Fierro; Manuela Velásquez; Angela P Cadavid; Karina de Leeuw
Journal:  Am J Reprod Immunol       Date:  2021-12-04       Impact factor: 3.777

Review 5.  Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications.

Authors:  Angela P Cadavid
Journal:  Front Immunol       Date:  2017-03-15       Impact factor: 7.561

6.  Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome.

Authors:  Manuela Velásquez; Luisa F Peláez; Mauricio Rojas; Raúl Narváez-Sánchez; Jesús A Velásquez; Carlos Escudero; Sebastián San Martín; Ángela P Cadavid
Journal:  Front Physiol       Date:  2021-12-02       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.